FDA Output
FDA Output, September 2026
Novel FDA Device Approvals, Breakthrough Designations, Class I Recalls, Warning Letters, and new Predetermined Change Control Plans in September 2026. Updated September 10.
Welcome to MyStrategist
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
Business Strategies
The NASS Innovation Summit: Enthusiasm for Spine Entrepreneurship in a Tough Market
At a NASS Summit on Spine Innovation, battle-hardened entrepreneurs, surgeons, investors, and healthcare system executives discussed lessons learned and takeaways for building companies in a financially constrained environment.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
Pathways’ Pick of the Week
Pathways' Picks of the Week: India Harmonizes, Streamlines
The country amends its regulations to further rely on EU CE marks, and makes other simplifications. Excerpted from Pathways Picks August 26: India Harmonization, Digital Health Updates, FDA Home Challenge, and More.